XHKG
8329
Market cap19mUSD
Oct 09, Last price
0.09HKD
1D
0.00%
1Q
-24.59%
Jan 2017
-81.03%
IPO
-72.54%
Name
Shenzhen Neptunus Interlong Bio-technique Co Ltd
Chart & performance
P/E
—
P/S
0.14
EPS
—
Div yield, %
170.33%
Shrs. gr., 5y
—
Rev. gr., 5y
-1.18%
Revenues
972m
-6.69%
Net income
-41m
L
CFO
140m
+471.77%
Dividend
May 15, 20250.1567 HKD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Based in Shenzhen, People's Republic of China, Shenzhen Neptunus Interlong Bio-technique Company Limited and its subsidiaries are primarily engaged in the research, development, production, and sale of pharmaceuticals. The company also handles the procurement, distribution, and marketing of medicines and health food items, while undertaking research and development in biological technology. Its manufacturing operations encompass herbal medicines, generic drugs, and medical devices. This entity operates as a subsidiary of Shenzhen Neptunus Bio-engineering Company Limited.
Key people
Executive Chairman of the Board, Compliance Officer · since 2011
Jian Bo Huang
Vice General Manager, Joint Company Secretary, Executive Director · since 2022
Xiao Guang Zhang
Executive Director · since 2023
Man Chao Wang
Executive General Manager - Jiangsu Neptunus
Hang Yuan
General Manager - Neptunus Nano · since 2014
Wai Sum Fung
Joint Company Secretary · since 2020
Ling Xia Mu
Company Secretary · since 2020
Rui Jin
Non-Executive Director · since 2022
Lin Yu
Non-Executive Director · since 2005
Yi Fei Zhang
Non-Executive Director · since 2021
Independent Non-Executive Director · since 2005
Independent Non-Executive Director · since 2005
Jian Zhou Zhang
Independent Non-Executive Director · since 2016
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||